PsiOxus Therapeutics Ltd. logo

PsiOxus Therapeutics Ltd.

PsiOxus Therapeutics engages in developing novel therapeutics for cancer and serious diseases. PsiOxus Therapeutics is a clinical stage biotech company, developing self replicating virus based immunotherapies for the treatment of cancer and wasting diseases.

PsiOxus was formed through the merger of Myotec Therapeutics (a portfolio company of Imperial Innovations Group plc) with Hybrid Biosystems (a biotech company developing gene therapy for the treatment of cancer).

Research Pipeline
BioStartup's Score 0 / 50


Disease Focus
Development Stage
4-10, The Quadrant, Abingdon Science Park, Barton Lane, Oxfordshire, OX14 3YS
United Kingdom
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”” connections=”true” suffix=””]

PsiOxus platform technology EnAd oncolytic vaccine is an engineered virus based vaccine that selectively replicated insid cancer cells and induce their death. The dying cancer cells provoke an immune response that further amplifies the process within the tumor environment, representing a new generation of Çself-amplifying cancer therapies.

In Dec 2016, PsiOxus signed an agreement granting Bristol-Myers Squibb an exclusive worldwide rights to NG-348, a solid tumor targeting oncolytic virus therapy. Under the terms, BMS paid PsiOxus a $50 Mn upfront payment and will be solely responsible for global clinical development and commercialization activities related to NG-348. PsiOxus is also eligible to receive up to $886 million in development, regulatory and sales-based milestones, as well as royalties on net sales. BMS also funds the preclinical development of NG-348. In Dec 2017, PsiOxus recieved $15 Mn as milestone payment from BMS on the approval of Clinical Trial Application for NG-348.

In June 2016, Bristol-Myers Squibb and PsiOxus, signs a clinical collaboration agreement to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus enadenotucirev, in combination with BMSs Immuno-Oncology drug Opdivo (nivolumab) to treat a range of tumor types in late-stage cancer patients. Under the terms, BMS will make a one-time upfront payment of $10 Mn to PsiOxus, and the parties will share development costs. Additionally, the companies will work exclusively with each other on anti- PD-1/PD-L1 antagonist antibody and enadenotucirev combination regimens, and BMS will have a time-limited right of exclusive negotiation for commercial rights to enadenotucirev.

In May 2015, PsiOxus raised £25 Mn in Series C financing to progress its lead clinical candidate. Founding investor Imperial Innovations led the round along with Woodford Investment, Invesco, SROne, Lundbeckfond Ventures and Mercia Technologies.

In July 2012, PsiOxus secured £22 Mn ($34 Mn) in Series B financing to drive Clinical Development of Oncolytic Cancer Vaccines. The key investors are Imperial Innovations Group, Invesco Perpetual, SR One and Lundbeckfond Ventures.